Pelvic Cancer Registry for Online Adapted Radiotherapy
Pelvic and Thoracic Cancer Treated With Online Adapted Radiotherapy: A Prospective Registry-based Phase-II Trial
University Medical Center Goettingen
846 participants
Jan 1, 2024
OBSERVATIONAL
Conditions
Summary
This prospective registry-based trial will include patients with pelvic or thoracic tumors with an indication for radiotherapy treated with oART or IGRT. For the primary endpoint and the secondary clinical endpoints, the trial will compare oART versus IGRT, for technical endpoints the trial will compare the real oART scenario with two virtual (hypothetical) control scenarios. Primary endpoint: * 10% reduction in the rate of acute radiotherapy related toxicity (≥ CTCAE II°, v5.0) using oART Secondary endpoints: * Clinical endpoints: Tumor control, late toxicities compared to conventional irradiated patients, quality of life and patient-reported outcomes * Technical endpoints: Target volume, target coverage, dose to organs at risk, anatomical variability score
Eligibility
Inclusion Criteria3
- Patients with pelvic or thoracic tumors with an indication for radiotherapy
- Patient information and declaration of consent
- Patients age ≥ 18 years
Exclusion Criteria1
- Prior radiotherapy in affected site
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06185062